Report from extraordinary general meeting in Active Biotech and adjustment of previously communicated timetable for the rights issue

    NEXT STORY
    HIV-Like Virus Eliminated from the Genomes of Primates; Excision BioTherapeutics Advancing the Innovation to Clinical Development
    PREV STORY
    Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    GBT Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and GBT021601

    author_avatar
    NASDAQ Market News

    CytomX Therapeutics Announces Proposed Public Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...

    author_avatar
    NASDAQ Market News

    SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones

    author_avatar
    NASDAQ Market News